Casodex vs Placebo in Non-metastatic Early Prostate Cancer - SPCG6
Study identifier:D6876C00025
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily with Placebo in Patients with Non-metastatic Prostate Cancer.
Medical condition
Non-metastatic prostate cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Bicalutamide, Placebo
Sex
Male
Actual Enrollment
1218
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Oct 1995
Primary Completion Date: -
Study Completion Date: 01 Aug 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Scandinavian Prostate Cancer Group
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: A | - |
| Active Comparator: B | Drug: Bicalutamide 150mg p.o. daily Other Name: Casodex |
Contacts
Investigators
Principal Investigator
Peter Iversen
Department of Urology Rigshospitalet Copenhagen, Denmark
